Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2010

View Archived Issues

Concert Pharmaceuticals claims new inhibitors of VEGFR-1, -2 and -3

Clinical data disclosed on Locteron/ribavirin vs. PEG-Intron/ribavirin in HCV genotype 1

Synta claims new dual CRAC and IL-2 inhibitors

Actelion claims novel orexin receptor antagonists

U.S. scientists claim new fused diimidazodiazepine agents

Pfizer details discovery and activity of dual PI3K/mTOR inhibitor PF-04691502

Phase II data presented on pasireotide in Cushing's disease and acromegaly

In vivo safety and antitumor activity of ABI-013 disclosed

L-Hyd4FC shows potent in vivo activity in HBV-infected mice

MK-5172 shows potent preclinical activity against resistance-linked HCV NS3/4a protease variants

Enrollment complete in OSI's phase III trial of erlotinib in NSCLC

Vertex provides pipeline update for first quarter of 2010

Erythropoietin does not show benefit in pediatric cardiac surgery

Osiris achieves milestone for remestemcel-L development progress in Japan

Clovis and Ventana to jointly develop diagnostic test for CO-1.01 trial in pancreatic cancer

ChronTech provides update on ChronSeal and ChronVac-C trials

FDA grants orphan drug status to Atir for the reduction of transplant-related mortality

Covidien launches Exalgo extended-release tablets in U.S. for pain management

Dexlansoprazole now available under new name Dexilant in U.S.

Pharmaxis resubmits Adriol NDA to FDA for diagnosis of asthma

Phase II brostallicin/cisplatin trial in triple-negative breast cancer planned

NeuroSearch claims new dopamine and serotonin receptor modulators

AdventRx to resubmit ANX-530 NDA in fourth quarter of 2010

BioCryst reports on phase IIa trial of BCX-4208 in patients with gout

DARA and NCI collaborate to advance KRN-5500 in cancer trial

Diamyd Medical continues phase III trials of Diamyd in diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...